NewAmsterdam Pharma Co N.V (NAMS) Receivables - Other: 2023-2025
Historic Receivables - Other for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $3.9 million.
- NewAmsterdam Pharma Co N.V's Receivables - Other rose 136.88% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 136.88%. This contributed to the annual value of $1.7 million for FY2024, which is 99.77% up from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Receivables - Other is $3.9 million, which was up 18.55% from $3.3 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Expense - Property Taxes and Insurance registered a high of -$1.0 million during Q2 2023, and its lowest value of -$1.0 million during Q2 2023.
- Moreover, its 3-year median value for Receivables - Other was $1.9 million (2024), whereas its average is $2.4 million.
- Over the last 5 years, NewAmsterdam Pharma Co N.V's Receivables - Other had its largest YoY gain of 136.88% in 2025, and its largest YoY loss of 63.81% in 2025.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's Receivables - Other (Quarterly) stood at $875,000 in 2023, then spiked by 99.77% to $1.7 million in 2024, then spiked by 136.88% to $3.9 million in 2025.
- Its Receivables - Other was $3.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and $1.4 million in Q1 2025.